The last time I wrote about 4D Molecular Therapeutics, Inc. (FDMT), it was in a Seeking Alpha article entitled “4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024.” In this ...
4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...
SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...
EMERYVILLE, CA--(Marketwired - January 07, 2016) - 4D Molecular Therapeutics (4DMT), a leader in Adeno-Associated Virus (AAV) gene therapy vector discovery and product development, today announced ...
4D Molecular Therapeutics (FDMT) has several clinical programs in its pipeline, with one of them being 4D-710 being advanced for the treatment of patients with Cystic Fibrosis [CF]. The most recent ...
SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback